Shurin MR - Search Results

1

CD154 inhibits tumor-induced apoptosis in dendritic cells and tumor growth.

Esche C, Gambotto A, Satoh Y, Gerein V, Robbins PD, Watkins SC, Lotze MT, Shurin MR. Esche C, et al. Among authors: shurin mr. Eur J Immunol. 1999 Jul;29(7):2148-55. doi: 10.1002/(SICI)1521-4141(199907)29:07<2148::AID-IMMU2148>3.0.CO;2-F. Eur J Immunol. 1999. PMID: 10427977 Free article.

2

Dendritic cells presenting tumor antigen.

Shurin MR. Shurin MR. Cancer Immunol Immunother. 1996 Nov;43(3):158-64. doi: 10.1007/s002620050317. Cancer Immunol Immunother. 1996. PMID: 9001569 Review.

3

FLT3 ligand induces the generation of functionally active dendritic cells in mice.

Shurin MR, Pandharipande PP, Zorina TD, Haluszczak C, Subbotin VM, Hunter O, Brumfield A, Storkus WJ, Maraskovsky E, Lotze MT. Shurin MR, et al. Cell Immunol. 1997 Aug 1;179(2):174-84. doi: 10.1006/cimm.1997.1152. Cell Immunol. 1997. PMID: 9268501

4

Dendritic cell based therapy of cancer.

Lotze MT, Shurin M, Davis I, Amoscato A, Storkus WJ. Lotze MT, et al. Adv Exp Med Biol. 1997;417:551-69. doi: 10.1007/978-1-4757-9966-8_91. Adv Exp Med Biol. 1997. PMID: 9286419 Review. No abstract available.

5

Antitumor activities of IL-12 and mechanisms of action.

Shurin MR, Esche C, Péron JM, Lotze MT. Shurin MR, et al. Chem Immunol. 1997;68:153-74. doi: 10.1159/000058690. Chem Immunol. 1997. PMID: 9329221 Review. No abstract available.

6

FLT3 ligand administration inhibits tumor growth in murine melanoma and lymphoma.

Esche C, Subbotin VM, Maliszewski C, Lotze MT, Shurin MR. Esche C, et al. Among authors: shurin mr. Cancer Res. 1998 Feb 1;58(3):380-3. Cancer Res. 1998. PMID: 9458075

7

FLT3: receptor and ligand. Biology and potential clinical application.

Shurin MR, Esche C, Lotze MT. Shurin MR, et al. Cytokine Growth Factor Rev. 1998 Mar;9(1):37-48. doi: 10.1016/s1359-6101(97)00035-x. Cytokine Growth Factor Rev. 1998. PMID: 9720755 Review.

8

Bone marrow-derived dendritic cells pulsed with a tumor-specific peptide elicit effective anti-tumor immunity against intracranial neoplasms.

Okada H, Tahara H, Shurin MR, Attanucci J, Giezeman-Smits KM, Fellows WK, Lotze MT, Chambers WH, Bozik ME. Okada H, et al. Among authors: shurin mr. Int J Cancer. 1998 Oct 5;78(2):196-201. doi: 10.1002/(sici)1097-0215(19981005)78:2<196::aid-ijc13>3.0.co;2-9. Int J Cancer. 1998. PMID: 9754652 Free article.

9

FLT3-ligand administration inhibits liver metastases: role of NK cells.

Péron JM, Esche C, Subbotin VM, Maliszewski C, Lotze MT, Shurin MR. Péron JM, et al. Among authors: shurin mr. J Immunol. 1998 Dec 1;161(11):6164-70. J Immunol. 1998. PMID: 9834102

10

Potentiation of E7 antisense RNA-induced antitumor immunity by co-delivery of IL-12 gene in HPV16 DNA-positive mouse tumor.

He YK, Lui VW, Baar J, Wang L, Shurin M, Almonte C, Watkins SC, Huang L. He YK, et al. Gene Ther. 1998 Nov;5(11):1462-71. doi: 10.1038/sj.gt.3300769. Gene Ther. 1998. PMID: 9930299

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

178 results

Search Page